Agios Pharmaceuticals, Inc.
corporate_fare Company Profile
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for AGIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AGIO spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Agios Q3: Revenue $55.4M, Loss Narrows to $1.09/Share, $907M Cash
- Agios Q3 Revenue Reaches $55.4M as Sickle Cell PDUFA Slips to February 2027
- Agios Posts $1.09 Per-Share Q3 Loss as Mitapivat Decision Slips to February
- FDA Pushes Mitapivat Sickle Cell Decision to February 2027 After Major Amendment
- Agios Q2 Revenue Triples on AQVESME Launch; Sickle Cell PDUFA Set for Nov 1
Financial Snapshot
Short Interest & Short Volume
5.17 days to coverFINRA reported short interest of 6,524,140 shares in AGIO as of the October 30, 2026 settlement, a 5.4% decrease from the prior period — about 5.2 days to cover at its recent average daily volume. On November 20, 2026, 43.7% of AGIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.